Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables (2016 - 2026)

Heron Therapeutics filings provide 12 years of Receivables readings, the most recent being $83.7 million for Q1 2026.

  • On a quarterly basis, Receivables rose 6.3% to $83.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $83.7 million, a 6.3% increase, with the full-year FY2025 number at $89.9 million, up 13.63% from a year prior.
  • Receivables hit $83.7 million in Q1 2026 for Heron Therapeutics, down from $89.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $89.9 million in Q4 2025 to a low of $40.3 million in Q2 2022.
  • Median Receivables over the past 5 years was $67.0 million (2024), compared with a mean of $66.6 million.
  • Biggest five-year swings in Receivables: dropped 5.43% in 2022 and later soared 90.29% in 2023.
  • Heron Therapeutics' Receivables stood at $58.2 million in 2022, then grew by 3.78% to $60.4 million in 2023, then surged by 30.93% to $79.1 million in 2024, then rose by 13.63% to $89.9 million in 2025, then decreased by 6.94% to $83.7 million in 2026.
  • The last three reported values for Receivables were $83.7 million (Q1 2026), $89.9 million (Q4 2025), and $81.0 million (Q3 2025) per Business Quant data.